Beijing HuayiHuilang Medical Instrument Co., Ltd. to distribute GA-mapTM Dysbiosis Test in China
Biohit Oyj Press Release August 22, 2016 at 09:30 am local time (EEST)
Biohit Oyj and Beijing HuayiHuilang Medical Instrument Co., Ltd. have signed an agreement for the distribution of the GA-mapTM Dysbiosis Test in China.
GA-mapTM Dysbiosis Test allows measuring of gut microbiota imbalance, dysbiosis. The test is particularly suitable for patients suffering from inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). The test reports the intestinal bacterial profile and balance of the microbiota, which helps guiding the treatment or changing the dietary habits in cases of imbalance. GA-mapTM Dysbiosis Test is CE-marked. Biohit Oyj has an exclusive right to distribute the test in Finland and China.
General Director Yisheng Fang, Beijing HuayiHuilang Medical Instrument Co., Ltd.: ‘Dysbiosis causes not only gut diseases, but is associated with other health problems as well. However, there has not been any reliable diagnostic test like Biohit Dysbiosis test in China as yet. China has a large and potential market for Dysbiosis Test. We have started the registration process in China that is a prerequisite for the marketing authorisation of the test.’
CEO Semi Korpela, Biohit Oyj: ‘Numerous studies have suggested the role of gut microbiota in gastrointestinal diseases, but the links between dysbiosis and IBS or IBD have been discovered only recently. Following the new agreement, Beijing HuayiHuilang Medical Instrument Co., Ltd receives the rights to distribute GA-mapTM Dysbiosis Test in China, which is an important market area for Biohit.’
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
GA-mapTM Dysbiosis Test product brochure
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com www.biohithealthcare.com/additional-information
Beijing HuayiHuilang Medical Instrument Co., Ltd. in brief
Beijing HuayiHuilang Medical Instrument Co., Ltd. (Huayi) is a professional medical device and IVD distribution company headquartered in Beijing, China. Huayi has a highly experienced sales team and well-established sales network in all regions of China. The company has cooperation with well-known clinical experts and doctors and a strong ability to promote sales. The customers of Huayi can be found all over China.